Talk:Ibutamoren

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Pharmacology (Rated Start-class, Low-importance)
WikiProject icon This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.
Start-Class article Start  This article has been rated as Start-Class on the project's quality scale.
 Low  This article has been rated as Low-importance on the project's importance scale.
 

Increased Blood Glucose Levels[edit]

Does this drug increase Blood Glucose Levels in t he Diabetic??? — Preceding unsigned comment added by 208.46.106.5 (talk) 21:21, 14 August 2015 (UTC)

Increased cortisol in elderly[edit]

Reference 7 says that MK677 doesn't increase cortisol, but a 2008 study involving the elderly showed that it did infact increase cortisol levels.

RESULTS: Daily administration of MK-677 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy young adults without serious adverse effects. Mean fat-free mass decreased in the placebo group but increased in the MK-677 group (change, -0.5 kg [95% CI, -1.1 to 0.2 kg] vs. 1.1 kg [CI, 0.7 to 1.5 kg], respectively; P < 0.001), as did body cell mass, as reflected by intracellular water (change, -1.0 kg [CI, -2.1 to 0.2 kg] vs. 0.8 kg [CI, -0.1 to 1.6 kg], respectively; P = 0.021). No significant differences were observed in abdominal visceral fat or total fat mass; however, the average increase in limb fat was greater in the MK-677 group than the placebo group (1.1 kg vs. 0.24 kg; P = 0.001). Body weight increased 0.8 kg (CI, -0.3 to 1.8 kg) in the placebo group and 2.7 kg (CI, 2.0 to 3.5 kg) in the MK-677 group (P = 0.003). Fasting blood glucose level increased an average of 0.3 mmol/L (5 mg/dL) in the MK-677 group (P = 0.015), and insulin sensitivity decreased. The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain. Low-density lipoprotein cholesterol levels decreased in the MK-677 group relative to baseline values (change, -0.14 mmol/L [CI, -0.27 to -0.01 mmol/L]; -5.4 mg/dL [CI, -10.4 to -0.4 mg/dL]; P = 0.026); no differences between groups were observed in total or high-density lipoprotein cholesterol levels. Cortisol levels increased 47 nmol/L (CI, 28 to 71 nmol/L (1.7 microg/dL [CI, 1.0 to 2.6 microg/dL]) in MK-677 recipients (P = 0.020). Changes in bone mineral density consistent with increased bone remodeling occurred in MK-677 recipients. Increased fat-free mass did not result in changes in strength or function. Two-year exploratory analyses confirmed the 1-year results.


[1]

Full text of the study is available for free via Pubmed link. — Preceding unsigned comment added by 2602:306:35BA:23D0:B5DD:76F4:DC32:FB71 (talk) 05:05, 17 April 2016 (UTC)

  1. ^ Nass R, E. A. Nass R, et al. 2016. "Effects Of An Oral Ghrelin Mimetic On Body Composition And Clinical Outcomes In Healthy Older Adults: A Randomized Trial. - Pubmed - NCBI ". Ncbi.Nlm.Nih.Gov. Accessed April 17 2016. http://www.ncbi.nlm.nih.gov/pubmed/18981485.